Furosemide oral tablet [Regulatives / Guidelines]

posted by Ibrahim Komeil – Egypt, 2019-11-18 09:03 (437 d 04:14 ago) – Posting: # 20818
Views: 863

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?

Complete thread:

Activity
 Admin contact
21,317 posts in 4,447 threads, 1,489 registered users;
online 15 (0 registered, 15 guests [including 6 identified bots]).
Forum time: Thursday 13:17 CET (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5